Provenire Capital’s Axcelis ACLS Stock Holding History

Provenire Capital’s Portfolio ACLS Stock Details ACLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-5,703	Closed	-$234K	–	43
2021 Q1	$234K	Sell	5,703 -40,282	-88%	-$1.5M	0.97%	39
2020 Q4	$1.34M	Buy	+45,985	New	+$1.19M	2.41%	19

Other funds holding ACLS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Provenire Capital's ACLS Position: Q2 2021 in Review

Provenire Capital sold out of Axcelis (ACLS) in Q2 2021, closing a stake of 5,703 shares — an estimated $234K sold.

Provenire Capital first reported a position in ACLS in Q4 2020 and held it in 2 quarters. The position peaked at $1.34M in Q4 2020. 189 funds tracked by Wall St. Rank hold ACLS as of Q2 2021.

Provenire Capital reported no remaining Axcelis position as of Q2 2021 after selling out during the quarter.
Provenire Capital sold 5,703 Axcelis shares in Q2 2021, an estimated $234K.
Provenire Capital first reported a position in Axcelis in Q4 2020 and held it in 2 quarters.
Provenire Capital's Axcelis position peaked at $1.34M in Q4 2020.
189 funds tracked by Wall St. Rank held Axcelis as of Q2 2021.

Based on Provenire Capital's 13F filing for Q2 2021, filed 16 Aug 2021.